{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:16:53Z","timestamp":1790781413393,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tafasitamab, a CD19\u2010targeting immunotherapy, is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B\u2010cell lymphoma (R\/R DLBCL) ineligible for autologous stem cell transplant. This real\u2010world study describes patient characteristics, treatment patterns, and outcomes associated with tafasitamab for R\/R DLBCL across US practice settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective physician\u2010abstracted chart review was conducted among US adults initiating tafasitamab (with\/without lenalidomide) for R\/R DLBCL as part of routine clinical care. Data were summarized using descriptive statistics. Cox proportional hazards\u2010based analyses were performed to determine baseline characteristics associated with real\u2010world progression\u2010free survival and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty\u2010three physicians (83% community physicians) provided data on 181 patients (64% White; median follow\u2010up since initiation, 14.7 months) meeting eligibility criteria. Most patients (72%) received tafasitamab as second\u2010line (2L) therapy. Real\u2010world overall response rate (95% CI) to tafasitamab was 73.5% (67.0\u201379.9). Median (95% CI) real\u2010world progression\u2010free survival and overall survival from tafasitamab initiation were 11.3 (9.8\u201313.6) and 24.8 (17.8\u2013NE) months, respectively. In multivariable Cox proportional hazards\u2010based analyses, tafasitamab use in third\u2010line to fifth\u2010line (3L\u20135L) (vs. 2L), bulky disease (vs. non\u2010bulky), Ann Arbor Stage III\u2013IV (vs. stage I\u2013II), and increasing Charlson Comorbidity Index scores were determined as factors associated with increased progression risk. In addition, increasing age, tafasitamab in 3L\u20135L (vs. 2L), bulky disease (vs. non\u2010bulky), and Eastern Cooperative Oncology Group performance status (ECOG PS) \u2265\u00a02 (vs. &lt;\u00a02) were associated with higher mortality risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This analysis of a diverse US population who received tafasitamab for R\/R DLBCL predominantly in community practice settings supports the clinical benefit of tafasitamab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>The authors have confirmed clinical trial registration is not needed for this submission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70256","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:17:49Z","timestamp":1774567069000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Real\u2010World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B\u2010Cell Lymphoma in the United States"],"prefix":"10.1002","volume":"7","author":[{"given":"Kim","family":"Saverno","sequence":"first","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma University of Texas MD Anderson Cancer Center  Houston Texas USA"},{"name":"Southwest Oncology CommonSpirit Oncology Mercy  Durango Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Cardinal Health  Dublin Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Galvin","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prathamesh","family":"Pathak","sequence":"additional","affiliation":[{"name":"Cardinal Health  Dublin Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Amoloja","sequence":"additional","affiliation":[{"name":"Incyte Corporation  Wilmington Delaware USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Gentile","sequence":"additional","affiliation":[{"name":"Cardinal Health  Dublin Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Asgarisabet","sequence":"additional","affiliation":[{"name":"Cardinal Health  Dublin Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"Division of Hematology The Ohio State University  Columbus Ohio USA"},{"name":"Division of Hematology and Hematologic Malignancies Huntsman Cancer Institute University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26151"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.12.001"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70282\u20107"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.004"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.21037\/aol.2019.09.01"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.06.012"},{"key":"e_1_2_12_8_1","unstructured":"\u201cMONJUVI\u00ae. Prescribing Information \u201dIncyte Corporation accessed November 19 2024 https:\/\/www.monjuvi.com\/pi\/monjuvi\u2010pi.pdf."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30225\u20104"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.275958"},{"key":"e_1_2_12_11_1","unstructured":"\u201cFDA Grants Accelerated Approval to Tafasitamab\u2010Cxix for Diffuse Large B\u2010Cell Lymphoma \u201dU. S. Food & Drug Administration accessed November 21 2024 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010tafasitamab\u2010cxix\u2010diffuse\u2010large\u2010b\u2010cell\u2010lymphoma."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010167753"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010162587"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021274"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2371472"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000971492.92995.27"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409\u2010023\u201002148\u20104"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2442053"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18552"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36741"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20101962"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283480"},{"key":"e_1_2_12_26_1","unstructured":"L. H.Sehn \u201cInternational Prognostic Index for Diffuse Large B\u2010Cell Lymphoma (IPI and R\u2010IPI) \u201dMDCalc acessed November 19 2024 https:\/\/www.mdcalc.com\/calc\/3936\/international\u2010prognostic\u2010index\u2010diffuse\u2010large\u2010b\u2010cell\u2010lymphoma\u2010ipi\u2010r\u2010ipi#evidence."}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70256","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T17:15:47Z","timestamp":1777223747000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/jha2.70256"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70256","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"2025-12-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70256"}}